Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.uniQure, a Netherlands-based provider of human gene therapy, has an exclusive distribution agreement with Medison Pharma, an Israeli healthcare marketing group.
Subscribe to our email newsletter
Under the deal, Medison will market Glybera, uniQure’s gene therapy product for the treatment of lipoprotein lipase deficiency (LPLD), in Israel and the Palestinian Authority.
Medison will also be responsible for securing regulatory approval for Glybera in both territories.
In the European Union (EU), Glybera is approved as a treatment for LPLD, a potentially life-threatening, orphan metabolic disease that results in patients’ inability to process fat in the blood after a meal.
Medison founder and CEO Meir Jakobsohn said, "Glybera represents an exciting opportunity for Medison to continue its leadership in offering new innovative treatments in Israel."
uniQure chief executive officer Jörn Aldag said after carefully evaluating different commercialization strategies for Glybera in the Israeli market, the company has concluded that partnering Glybera allows it to optimize the value of the asset as we continue to develop its pipeline.
"Medison has a well-established and significant commercial organization in Israel with a proven track record in successfully marketing specialty products," Aldag said.
"Through this partnership Glybera will be available to LPLD patients in Israel and the Palestinian Authority sooner than otherwise possible.
"uniQure remains focused on the advance of Glybera toward the initiation of the regulatory process in the USA this year, as well as the further development of our candidate gene therapies currently in the clinic."